LON:AREC

Arecor Therapeutics Final Earnings Results & Report

Arecor Therapeutics logo
GBX 72 -4.00 (-5.26%)
As of 11/20/2026 09:56 AM Eastern

Arecor Therapeutics reported Final earnings on April 13, 2026. The company reported EPS of GBX 2, while revenue was £1.71 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Arecor Therapeutics EPS Results

Actual EPS
GBX 2
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Arecor Therapeutics Revenue Results

Actual Revenue
£1.71 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Arecor Therapeutics Final Earnings FAQ

Arecor Therapeutics (LON:AREC) reported earnings of GBX 2 per share for Final. The report was announced on Monday, April 13, 2026.

Arecor Therapeutics reported revenue of £1.71 million for Final.

Arecor Therapeutics Earnings Headlines

Arecor Therapeutics PLC
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Patents for concentrated ultra-rapid insulins
Arecor Therapeutics adds patents as it eyes $3 billion US market
See More Arecor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email.

About Arecor Therapeutics

Arecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.

View Arecor Therapeutics Profile